media.biogen.comBiogen | News

media.biogen.com Profile

media.biogen.com

Title:Biogen | News

Description：The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.

Discover media.biogen.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site

media.biogen.com Information

Website / Domain:	media.biogen.com
HomePage size:	52.31 KB
Page Load Time:	0.025676 Seconds
Website IP Address:	23.194.131.146
Isp Server:	Akamai Technologies Inc.

media.biogen.com Ip Information

Ip Country:	United States
City Name:	Ashburn
Latitude:	39.043720245361
Longitude:	-77.487487792969

media.biogen.com Keywords accounting

Keyword	Count

media.biogen.com Httpheader

Accept-Ranges: bytes
Content-Encoding: gzip
Content-Language: en
Content-Type: text/html; charset=UTF-8
device: desktop
ETag: "1609756538"
Expect-CT: max-age=0, report-uri="/report-expect-ct-violation"
Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr none", From-Origin: same
Last-Modified: Mon, 04 Jan 2021 10:35:38 GMT
Link: http://media.biogen.com/news; rel="alternate"; hreflang="en", http://media.biogen.com/news; rel="canonical", http://media.biogen.com/node/5816; rel="shortlink", http://media.biogen.com/news; rel="revision"
Referrer-Policy: no-referrer-when-downgrade
X-Age: 839
X-Cache-Hits: 11
X-Content-Type-Options: nosniff
X-Drupal-Dynamic-Cache: UNCACHEABLE
X-Frame-Options: SAMEORIGIN
X-Request-ID: v-95f818be-4e78-11eb-85cb-7b1172433c62
X-UA-Compatible: IE=edge
X-XSS-Protection: 1; mode=block
Content-Length: 11207
Cache-Control: public, max-age=0, s-maxage=1800
Expires: Mon, 04 Jan 2021 10:53:52 GMT
Date: Mon, 04 Jan 2021 10:53:52 GMT
Connection: keep-alive
Vary: Accept-Encoding
Set-Cookie: DrupalVisitorMobile=0; path=/; Secure; HttpOnly

media.biogen.com Meta Info

charset="utf-8"/
content="Biogen" property="og:site_name"/
content="website" property="og:type"/
content="http://media.biogen.com/news" property="og:url"/
content="News \| Biogen" property="og:title"/
content="no-referrer" name="referrer"/
content="The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts." property="og:description"/
content="Drupal 8 (https://www.drupal.org)" name="Generator"/
content="width" name="MobileOptimized"/
content="true" name="HandheldFriendly"/
content="width=device-width, initial-scale=1.0" name="viewport"/

23.194.131.146 Domains

Domain	WebSite Title

media.biogen.com Similar Website

Domain	WebSite Title

media.biogen.com Traffic Sources Chart

media.biogen.com Alexa Rank History Chart

media.biogen.com Html To Plain Text

Skip to main navigation Top bar Biogen.com Information Request Sign up for Alerts Search Investor Relations Overview News Events & Presentations Events Presentations Financials SEC Filings Annual Reports Stock Information Stock Quote & Chart Analyst Coverage Investor FAQs Corporate Governance Governance Documents Committee Composition & Charters Leadership Code of Business Conduct Contact the Board News News News Category Biosimilars Collaborations Company Statements Corporate Investor Relations Neurodegenerative Diseases Rare and Genetic Diseases Year None 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 December 21, 2020 The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis December 9, 2020 Biogen Files New Drug Application for Aducanumab in Japan November 27, 2020 Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders November 18, 2020 Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab) November 16, 2020 Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership November 6, 2020 Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease November 3, 2020 Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020 November 3, 2020 Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting October 30, 2020 European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease October 21, 2020 Biogen Reports Q3 2020 Results Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 757 Footer Investors Careers Our Stories Contact Us Follow us Bottom Privacy Policy Terms & Conditions Forward-Looking Statements Community Guidelines Investor Relations Overview News Events & Presentations Events Presentations Financials SEC Filings Annual Reports Stock Information Stock Quote & Chart Analyst Coverage Investor FAQs Corporate Governance Governance Documents Committee Composition & Charters Leadership Code of Business Conduct Contact the Board Top bar Biogen.com Information Request Sign up for Alerts Search Follow us...

media.biogen.com Whois

"domain_name": [ "BIOGEN.COM", "biogen.com" ], "registrar": "CSC CORPORATE DOMAINS, INC.", "whois_server": "whois.corporatedomains.com", "referral_url": null, "updated_date": "2019-04-11 05:35:23", "creation_date": "1995-04-14 04:00:00", "expiration_date": "2020-04-15 04:00:00", "name_servers": [ "NS1.P28.DYNECT.NET", "NS2.P28.DYNECT.NET", "NS3.P28.DYNECT.NET", "NS4.P28.DYNECT.NET", "ns3.p28.dynect.net", "ns1.p28.dynect.net", "ns4.p28.dynect.net", "ns2.p28.dynect.net" ], "status": [ "clientTransferProhibited https://icann.org/epp#clientTransferProhibited", "clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited" ], "emails": [ "domainabuse@cscglobal.com", "domainnamesadmin@biogen.com" ], "dnssec": "unsigned", "name": "Biogen Idec MA Inc", "org": "Biogen Idec MA Inc", "address": null, "city": "Cambridge", "state": "Ma", "zipcode": "02142", "country": "US"